연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
2165. Improving the prediction of lung adenocarcinoma invasive component on CT: Value of a vessel removal algorithm during software segmentation of subsolid nodules.
Garzelli L, Goo JM, Ahn SY, Chae KJ, Park CM, Jung J, Hong H.
Eur J Radiol. 2018 Mar;100:58-65
Link
2164. The Potential Role of Grid-Like Software in Bedside Chest Radiography in Improving Image Quality and Dose Reduction: An Observer Preference Study
Ahn SY, Chae KJ, Goo JM
Korean J Radiol. 2018 May-Jun;19(3):526-533
Link
2163. Evaluation of T categories for pure ground-glass nodules with semi-automatic volumetry: is mass a better predictor of invasive part size than other volumetric parameters?
Kim H, Goo JM, Park CM
Eur Radiol. 2018 Oct;28(10):4288-4295
Link
2162. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M1, Kim TM2, Keam B1, Kim YJ3, Paeng JC4, Moon KC5, Kim DW1, Heo DS1.
Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.
Link
2161. Measurement of multiple solid portions in part-solid nodules for T categorization: Evaluation of prognostic implication
Kim H, Goo JM, Suh YJ, Hwang EJ, Park CM, Kim YT
J Thorac Oncol. 2018 Dec;13(12):1864-1872
Link
2160. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Kim DW1,2, Heo DS1,2.
Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.
Link
2159. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY1, Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Jeon YK3, Kim DW1,2, Chung DH3, Heo DS1,2.
Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]
Link
2158. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.
Cheun H1, Kim M2, Lee H2, Oh KH2, Keam B3,4.
Invest New Drugs. 2018 Oct 8. doi: 10.1007/s10637-018-0673-y. [Epub ahead of print]
Link
2157. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Kang SH1, Keam B1,2, Ahn YO1,3, Park HR1, Kim M2, Kim TM1,2, Kim DW1,2, Heo DS1,2.
Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.
Link
2156. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
Seo JS1,2,3,4, Kim A5,6,7, Shin JY6,8, Kim YT9,10,11.
Sci Rep. 2018 Oct 1;8(1):14576. doi: 10.1038/s41598-018-32855-8.
Link